debrisoquin has been researched along with Eosinophilia-Myalgia Syndrome in 1 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Eosinophilia-Myalgia Syndrome: A complex systemic syndrome with inflammatory and autoimmune components that affect the skin, fascia, muscle, nerve, blood vessels, lung, and heart. Diagnostic features generally include EOSINOPHILIA, myalgia severe enough to limit usual activities of daily living, and the absence of coexisting infectious, autoimmune or other conditions that may induce eosinophilia. Biopsy of affected tissue reveals a microangiopathy associated with diffuse inflammation involving connective tissue. (From Spitzer et al., J Rheumatol Suppl 1996 Oct;46:73-9; Blackburn WD, Semin Arthritis Rheum 1997 Jun;26(6):788-93)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mephenytoin S/R ratios were 0." | 1.29 | Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. ( Clauw, DJ; Flockhart, DA; Hewett, J; Sale, EB; Woosley, RL, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flockhart, DA | 1 |
| Clauw, DJ | 1 |
| Sale, EB | 1 |
| Hewett, J | 1 |
| Woosley, RL | 1 |
1 other study available for debrisoquin and Eosinophilia-Myalgia Syndrome
| Article | Year |
|---|---|
Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome.
Topics: Alleles; Arylamine N-Acetyltransferase; Case-Control Studies; Dapsone; Debrisoquin; Eosinophilia-Mya | 1994 |